| Patent application number | Description | Published |
|---|
| 20080227140 | TRP/HIS Exchange and Kynurenine Induced TRP Transport - The present invention provides methods for detecting changes in tryptophan concentrations in a cell and methods for identifying agents that modulate cellular tryptophan concentrations. In particular, the present invention provides methods for detecting cellular exchange between tryptophan and kynurenine, and methods for identifying agents that modulate this exchange. The present invention also provides methods for treating a disease associated with immunosuppression in a subject in need thereof. In particular, the present invention is directed toward a method of treating a disease associated with immunosuppression comprising contacting the disease with an agent that modulates cellular Trp/kynurenine exchange. Furthermore, the present invention provides methods for identifying an agent that modulates an immunosuppression. | 09-18-2008 |
| 20090054251 | Diagnosis of Autoimmune Disease - Methods and compositions for diagnosing and treating autoimmune disease, e.g., acute disseminated encephalomyelitis (ADEM), are described. | 02-26-2009 |
| 20090264515 | POLYNUCLEOTIDE THERAPY - This invention provides a method of treating or preventing a disease in an animal associated with one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present or involved in a non-physiologic process in the animal comprising administering to the animal a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) modulates an immune response to the self-protein(s), -polypeptide(s) or -peptide(s) expressed from administration of the self-vector. The invention also provides a composition comprising a polynucleotide encoding one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present non-physiologically in a treated animal useful in treating or preventing a disease associated with the self-protein(s), -polypeptide(s), or -peptide(s) present in and/or the target of a non-physiologic process in the animal. | 10-22-2009 |
| 20090281170 | POLYNUCLEOTIDE THERAPY - This invention provides a method of treating or preventing a disease in an animal associated with one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present or involved in a non-physiologic process in the animal comprising administering to the animal a self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) associated with the disease. Administration of the self-vector comprising a polynucleotide encoding the self-protein(s), -polypeptide(s) or -peptide(s) modulates an immune response to the self-protein(s), -polypeptide(s) or -peptide(s) expressed from administration of the self-vector. The invention also provides a composition comprising a polynucleotide encoding one or more self-protein(s), -polypeptide(s), or -peptide(s) that is present non-physiologically in a treated animal useful in treating or preventing a disease associated with the self-protein(s), -polypeptide(s), or -peptide(s) present in and/or the target of a non-physiologic process in the animal. | 11-12-2009 |
| 20090317357 | Methods for treating or preventing autoimmune disease using histamine h1 receptor-blocking agents - Methods for treating or preventing an autoimmune disease using agents that block the histamine H1 receptor are disclosed. H1 receptor-blocking agents useful in accordance with the methods provided herein include, for example, H1 antihistamines, particularly H1 antihistamines that do not substantially block the serotonin receptor. | 12-24-2009 |
| 20100129376 | Osteopontin Specific Antibodies and Methods of Use Thereof - Monoclonal antibodies immunospecific for osteopontin are disclosed. Also provided are therapeutic methods of use thereof for modulating osteopontin levels for the treatment of autoimmune disorders. | 05-27-2010 |
| 20100178292 | CRYPTIC GLYCAN MARKERS AND APPLICATIONS THEREOF - The present invention relates to a novel glycan marker of cancer and monoclonal antibodies against it. Furthermore, novel glycan markers and their use in the detection and monitoring of cancerous cells and cancer-associated or specific antibody signatures are described. | 07-15-2010 |
| 20110160142 | Alpha B-Crystallin as a therapy for inflammation - The invention provides methods for treating inflammatory diseases by administering to the subject an effective amount of an agent that provides alpha B-crystallin activity, where the dose is effective to suppress or prevent initiation, progression, or relapses of disease, including the progression of established disease. In some embodiments, the methods of the invention comprise administering to a subject having a pre-existing inflammatory disease condition, an effective amount of alpha B-crystallin protein, to suppress or prevent relapses of the disease. | 06-30-2011 |
